Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Proteostasis-related biomarkers

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Amyloid
Inflammation
Neuronal damage
Tau
Other
Use
Diagnostic
Monitoring
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

The overall aim of the subproject is to identify a panel of CSF biomarkers to further improve specificity of diagnosis ("disease markers"), to measure disease activity and to predict AD progression ("stage and progression markers"). Within this study, a panel of proteins, comprising Aβ- and Tau-species as well as inflammation, glial and synaptic markers, potentially involved in disease progression will be measured in biomaterial from baseline and from follow up assessment. Clinical data will be correlated with the panel of disease and progression markers.

Target Population/ Population Being Studied

AD patients and AD patients immunized

Length of Current Trial
3-5 years
Number of Trial Participants

200

Estimated Trial Completion
December 2019
What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Charite University, Berlin, Germany

“Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia.” ClinicalTrials.gov. Accessed October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT02686554?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=2